Relmada Therapeutics Inc

NASDAQ:RLMDUnited States

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

Contact Information

Headquarters

2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134

Phone

646-876-3459

Fax

---

Executives

Independent Chairman of the Board

Charles Casamento

Chief Executive Officer, Director

Sergio Traversa

Chief Financial Officer

Maged Shenouda

Chief Accounting, Compliance Officer

Charles Ence

Acting Chief Scientific Officer

Paolo Manfredi